The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis

By Abu-Alfa Ali K.   Sloan Lance   Charytan Chaim   Sekkarie Mohamed   Scarlata Debra   Globe Denise   Audhya Paul  

Current Medical Research and Opinion, Vol. 24, Iss. 4, 2008-04 ,pp. : 1091-1100

Informa Healthcare

Access to resources Recommend Favorite

The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease

By Cremieux Pierre-Yves   Van Audenrode Marc   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2329-2336

Informa Healthcare

Access to resources Recommend Favorite

Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa

By Hymes Jeffrey   Bickimer Tammy   Jackson James H.   Bookhart Brahim K.   Mody Samir H.   Tak Piech Catherine  

Current Medical Research and Opinion, Vol. 23, Iss. 8, 2007-08 ,pp. : 1931-1937

Informa Healthcare

Access to resources Recommend Favorite

Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease

By Einarson Thomas   Machado Marcio   Walker John   Iskedjian Michael   Cremieux Pierre-Yves   Van Audenrode Marc   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1571-1574

Informa Healthcare

Access to resources Recommend Favorite

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*

By Silver M. R.   Geronemus R.   Krause M.   Chen C. Y.   Kewalramani R.   Stehman-Breen C.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 123-131

Informa Healthcare

Access to resources Recommend Favorite